Current Market Information

Last Trade Price (LTP) 51.00 Last Trade Date 06 November, 2024 Change 0.79 % Open Price 50.60 Day's Range 50.30 - 51.70     Total Trade 21 Total Volume 5225 Close Price 51.00 Yesterday Close Price 50.60 Market Capital in BDT (mn) 5478.227

Contact Information

Designation Name Mobile Number Email Chairman Professor Dr. Sarder A. Nayeem MD Dr. Sayeed Ahmed CFO Mr. Hassan Shahid Sarwar FCA Company Secretary Mr. Lorens Shamol Mollick FCS 01321131222 secretary@navanapharma.com Office Address Plot 99, Road 04, Block B, Banani, Dhaka 1213 Phone : 02-55033580-3 Fax : 02-55033579 Email : cs@navanapharma.com Website : http://www.navanapharma.com Factory Address Rupshi, Rupganj, Narayanganj

Basic Information

Authorized Capital in BDT* (mn) 2,000.00 Paid-up Capital in BDT* (mn) 1,074.16 Face Value 10 Paid up Share 107416217     Market Lot 1 Sector PHARMA & CHEMICALS Market Category A

Other Information

Listing Year 2022 Debut Trade Date 18 October, 2022 Type of Instrument Equity     52 Week's Range 39.50 - 114.40 Year End 202306 Reserve / Surplus(mn) 2850.1 Remarks Tk. 1,848,295,335 Revaluation Reserve has been added to Reserve & Surplus. Note

Share Holding Percentage

Sponsor/Director Govt. Institute Foreign Public As on 30-Sep, 2024 36.17 0 8.49 19.62 35.72 As on 31-Aug, 2024 35.49 0 8.87 27.73 27.91 As on 31-Jul, 2024 35.49 0 9.02 27.73 27.76 As on 30-Jun, 2024 (year ended) 35.49 0 9.22 27.73 27.56     Remarks Note     Credit Rating Status Credit Rating Year Long Term Short Term Outlook Validity Date Credit Rating Company Aug 01, 2023 AA ST-2 Stable Jul 31, 2024 National Credit Rating Ltd. May 12, 2022 AA ST-2 Stable May 11, 2023 National Credit Rating Ltd.         Half Year End (HY) Information  202312 HY Net Turnover(mn)  3283.64 HY Net Profit after tax(mn)  224.32 HY EPS  2.09  AGM Information   AGM Date  31 December, 2024 Record Date  19 November, 2024 Dividend(%)  14.00 (Cash only for General Shareholders (Sponsor shareholders and Directors and few shareholders who hold significant share of the company will not receive any dividend-June 2024) Bonus Issue

   

Financial Performance
Performance Year	Basic EPS Based On		Basic EPS (restated) Based On		Net Asset Value Per Share	Restated Net Asset Value Per Share	Net Profit After Tax(mn)		% Dividend	% Dividend Yield
	Continuous operations	Including Extra-Ordinary Income	Continuous operations	Including Extra-Ordinary Income			Continuous operations	Including Extra-Ordinary Income
2023	3.59	0	0	0	40.71	0	356.94	0	13%C	1.11
2022	3.42	0	0	0	43.41	0	274	0	11%C	0
2021	2.52	0	1.88	0	41.19	37.74	202.29	0		0

Financial Statements
Quarterly Financial Statement	https://navanapharma.com/page/quarterly-accounts
Price Sensitive Information	https://navanapharma.com/page/psi

Close Price and Traded Volume Graph
Click here to view 1 month graph	Click here to view 3 month graph	Click here to view 6 month graph
Form	To